LAURINBURG — Doctors Greg Mincey and Arghavan Almony — diabetic eye, retina and vitreous specialists at Carolina Eye Associates — will be participating in a national clinical study comparing the efficacy and safety of a new treatment for neovascular age-related macular degeneration.
This will be a two-year, randomized study comparing the efficacy and safety of RTH258 verses Aflibercept in people with wet AMD.
“Carolina Eye is committed to addressing patients’ needs in retina and hopes to improve visual outcomes in patients with wet age-related macular degeneration,” said Almony. “The principal aim of treatment of neovascular AMD is to preserve visual acuity and to reduce the risk of additional severe vision loss for as long as possible.”
Study subjects must be at least 50 years of age with untreated active choroidal neovascularization secondary to age-related macular degeneration in the study eye.
If you think you may be a candidate for this study or have a patient who meets the criteria described above, contact Lisa Fulghum, cinical trials coordinator for Carolina Eye Associates, at 910-295-2100 ext. 881 or firstname.lastname@example.org.